World’s Leading Neuro-Oncology Experts to Join IAG’s Scientific Advisory Board

Slider with alias news slider not found.

World’s Leading Neuro-Oncology Experts to Join Our Scientific Advisory Board

Dr John Howard Sampson, Dr Benjamin Ellingson and Dr Ezra Cohen will joint IAG’s scientific advisory board to closely work with our in-house scientists, imaging experts and academic collaborators. The long-standing Scientific Advisory Board is fuelling IAG’s internal innovation efforts while helping bio-pharmaceutical partners to maximize the chances of success when developing novel therapeutic agents.

London, UK and Philadelphia, USA—IAG, Image Analysis Group, a unique partner to life science companies committed to its ambitious goal of bringing the best of technological innovation, AI and quantitative imaging to optimize the speed, cost and time of bio-pharmaceutical R&D, today announced the appointment of leading experts: John Howard Sampson, Ben Ellingson, and Ezra Cohen to IAG’s Scientific Advisory Board,

Dr. Sampson, Duke School of Medicine, M.D., Ph.D, M.B.A, M.H.S.c, joins as a recognized leader in the surgical resection and experimental treatment of complex brain tumours. An author of more than 240 peer-reviewed publications, his research led to the development of a vaccine against a common mutation in brain tumours, which has been given Breakthrough Therapy Designation by the FDA after demonstrating extended survival in patients with glioblastoma multiforme (GBM).

Dr. Ellingson, UCLA, PH.D., joins as an expert in the field of radiology, has co-authored over 90 peer-reviewed publications, and has extensive experience in imaging analysis across multi-centre clinical trials in brain cancer. Dr Ellingson serves as the Chair of the Neuro-Imaging Committee for the NIH-funded Adult Brain Tumour Consortium, Chair for the new Glioblastoma Global Adaptive Trial and co-chair of the imaging committee for specific brain tumour trials run by the alliance for clinical trials in Oncology.

Dr. Cohen, UCSD, MD, FRCPSC, FASCO, joins as a Board-Certified Oncologist and internally renowned Cancer Researcher. A frequent speaker at national and international meetings, he has authored more than 170 peer-reviewed papers and has been the principal investigator of multiple clinical trials of new drugs for head and neck cancer and other solid tumours in all phases of development. Dr. Cohen recently served as editor-in-chief of Oral Oncology, the most respected specialty journal in head and neck cancer, and recently chaired two Multidisciplinary Head and Neck Cancer Symposia—the largest international meeting of its kind—sponsored by the American Society for Radiation Oncology, the American Society of Clinical Oncology and the American Head and Neck Society. Dr. Cohen leads a laboratory that studies novel cancer treatments, including immunotherapy, and has made major contributions in understanding how targeted cancer therapies work. Dr Cohen also serves as co-director of the San Diego Center for Precision Immunotherapy.

‘As the company continue to grow and develop new partnerships across many oncology indications, it is our pleasure to welcome world’s leading experts to our Scientific Advisory Board,’ said Dr. Olga Kubassova, IAG’s CEO.

Increasing incidences of brain cancer have augmented the demand for brain cancer therapeutics across the globe, which is driving the market and clinical research efforts. Increased focus on precision medicine, use of advanced imaging, AI-driven methods for assessment of treatment efficacy are fuelling the global brain tumour therapeutics market. We look forward to supporting our biotech and pharma partners in their development programs‘, added Dr. Diana Roettger, Head of Therapeutic Innovation at IAG.

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.  IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:

Reach out:

Follow the Company: Linkedin